Leading Cardiothoracic Surgeon Joins Leadership Team as the Company Leverages its Proprietary nsPFA™ Technology for the Treatment of Atrial Fibrillation
. | May 3, 2023
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary nanosecond pulsed field ablation technology and proprietary CellFX System® for the treatment of atrial fibrillation,. | May 1, 2023